Jury Orders Johnson & Johnson (JNJ) to Pay $966M in Talc Verdict
Johnson & Johnson (NYSE:JNJ) is one of Ray Dalio’s latest top stock positions.
Johnson & Johnson (JNJ)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 14,479 | $2,684,674 | -7% | 1.25% |
| 2. | Zevenbergen Capital Investments Nancy Zevenbergen | 10,779 | $1,998,642 | +1% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $145.53 | 100 | $14,553.00 | 250 | 2024-04-30 | Filing | |
| $147.22 | 1,000 | $147,220.00 | 1,000 | 2024-12-12 | Filing | |
| $127.69 | 500 | $63,843.00 | 16,030 | 2020-03-13 | Filing | |
| $141.28 | 5,000 | $706,399.00 | 5,000 | 2019-12-13 | Filing | |
| $139.68 | 3,000 | $419,040.00 | 3,000 | 2019-06-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $177.81 | 56,471 | $10,040,882.63 | 178,013 | 2025-09-04 | Filing | |
| $179.21 | 125,824 | $22,548,654.81 | 275,967 | 2025-08-22 | Filing | |
| $176.91 | 16,820 | $2,975,570.69 | 14,000 | 2025-08-15 | Filing | |
| $163.55 | 19,137 | $3,129,829.56 | 10,658 | 2025-07-17 | Filing | |
| $165.88 | 6,999 | $1,160,994.12 | 21,001 | 2025-02-25 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,440,547 | $823,366,225 | 1.13% | |
| 2. | 2,177,506 | $403,753,162 | 0.41% | |
| 3. | 1,122,270 | $207,198,728 | 1.1% | |
| 4. | 985,024 | $182,403,438 | 0.18% | |
| 5. | 667,373 | $123,744,268 | 1.72% |
News See All
Johnson & Johnson's (JNJ) Stock Is Now Positioned To "Challenge Eli Lilly," Says Jim Cramer
Johnson & Johnson (NYSE:JNJ) announced yesterday that it would spin off its orthopedics business to allow it to become the largest firm of its kind in the world.
J&J Announces Second Major Spinoff, Plans to Separate Orthopedics Division
On October 14, the company announced that it will spin off its orthopedics division into a separate company within the next 18 to 24 months.
11 Defensive Healthcare Dividend Stocks To Buy Now
US healthcare stocks have been under mounting pressure this year, largely due to policies introduced by the Trump administration.
13 Stocks to Buy According to Billionaire Ray Dalio's Bridgewater Associates
“Expect deeper structural problems”. That was the sentiment echoed by Ray Dalio, the founder of the world's largest hedge fund by assets under management, Bridgewater Associates.
Jim Cramer Talked About These 8 Stocks & The Quantum Computing Dip
In his appearance on CNBC's Squawk on the Street yesterday, Jim Cramer discussed the recent selloff in quantum computing, crypto, and other stocks.
Johnson & Johnson (NYSE:JNJ) Q3 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Johnson & Johnson's Third Quarter 2025 Earnings Conference Call.
Johnson & Johnson’s (JNJ) Strong Dividend Track Record and Focus on Innovation
Johnson & Johnson (NYSE:JNJ) operates as a global healthcare leader, focusing primarily on pharmaceuticals and medical devices.
19 Stocks in Jim Cramer's Game Plan For This Week
“Now, we bought a little bit of stock, not a lot, for the Charitable Trust today, and we only did so because there could be some of that art of the deal thing going on.
Johnson & Johnson (JNJ): A Cornerstone Among the Most Profitable Dividend Stocks
Johnson & Johnson (NYSE:JNJ) is one of America’s most recognizable healthcare companies, with operations that now center on pharmaceuticals and medical devices.
Hedge Fund Resource Center Billionaire Hedge Funds
